Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA2 | P00918 | 4/20 | 0.56 |
| ▸ | ACHE | P22303 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 5/20 | 0.55 |
| ▸ | DRD3 | P35462 | 5/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346286 | 0.94 | CA1 (0.56) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL459626 | 0.91 | MTNR1A (0.50) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL436970 | 0.89 | MTNR1A (0.49) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL10197736 | 0.86 | HDAC1 (0.53) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL460204 | 0.86 | MTNR1A (0.46) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8074296 | 0.86 | MTNR1A (0.63) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL8606735 | 0.86 | MTNR1A (0.63) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL545767 | 0.86 | MTNR1A (0.63) | MTNR1AMTNR1BCA1CA2ACHE | |
| SCHEMBL345764 | 0.84 | MCHR1 (0.57) | — | |
| SCHEMBL345881 | 0.84 | MTNR1A (0.60) | MTNR1AMTNR1BCA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | MTNR1A 1579/4885MTNR1B 1240/4885CA1 400/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | MTNR1A 1442/4885MTNR1B 1160/4885CA1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.